Venkatesan brings more than 17 years of experience in regulatory affairs, regulatory compliance and quality engineering in the medical device and In Vitro Diagnostics industry
Boston-based biotech company NanoMosaic, the pioneer and leader in nanoneedle (MosaicNeedle) technology detection for proteomics, genomics, and single-run experiment multi-omics applications, has announced the appointment of Raaj Venkatesan as its Chief Regulatory Officer.
Venkatesan brings more than 17 years of experience in regulatory affairs, regulatory compliance and quality engineering in the medical device and In Vitro Diagnostics industry. Before joining Nanomosaic, Raaj served as a Regulatory Affairs and Quality executive at NovaSignal Corporation, Ancestry Health, the healthcare division of AncestryDNA and Exosome Diagnostics. Before that, Venkatesan held various regulatory affairs and quality engineering positions at Bio-Rad Laboratories, Bruker Daltonics, OmniGuide Surgical, Becton Dickinson (BD) Diabetes Care and Second Sight Medical Products.
Venkatesan is Regulatory Affairs Certified (RAC-US, RAC-EU) by the Regulatory Affairs Professionals Society (RAPS) and is also an ASQ Certified Manager of Quality, Reliability Engineer, Quality Auditor, Biomedical Auditor and Quality Engineer. He earned his Master’s Degree in Biomedical Engineering, Electrical Engineering and Medical Device and Diagnostic Engineering from the University of Southern California and a Bachelor’s Degree in Electronics and Instrumentation Engineering from Bharathidasan University in India.
“I am honoured and excited to join Nanomosaic at such an exciting time for the company and the proteomics space,” said Venkatesan. “With the assays that we are developing with our current Tessie system and the nanoneedle technology, I look forward to working closely with our team, customers and appropriate regulatory agencies to ensure the most effective deployment of our technology to clinicians and pharmaceutical organisations. Additionally, I am particularly eager to leverage our recent partnerships with academic and clinical researchers to overcome obstacles in the regulatory and commercialisation processes, and bring their assays as diagnostics to patients in need.”
